The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
03-Apr-25
Pending
$9.0 billion
Target:
Colonial Enterprises, Inc.
Acquiror:
Brookfield Infrastructure Group LLC
Advising Brookfield Infrastructure Partners LLC on its acquisition of Colonial Enterprises, Inc., which owns and operates the Colonial Pipeline, the largest refined products system in the U.S., spanning ~5,500 miles between Texas and the New York Harbor
25-Feb-25
Pending
$10 billion (CAD value)
Target:
Innergex Renewable Energy Inc.
Acquiror:
Caisse de dépôt et placement du Québec
Advising the Special Committee of Innergex Renewable Energy Inc. on its sale to Caisse de dépôt et placement du Québec and provided fairness opinions in respect of the transaction to the common shareholders and the holders of the Series A preferred shares
13-Feb-25
$890 million
Target:
Renewi plc
Acquiror:
Consortium controlled by Macquarie Asset Management and BCI
Advising Renewi plc, a leading European waste-to-product company, on its £707 million recommended cash offer for its entire issued share capital from a consortium controlled by Macquarie Asset Management and British Columbia Infrastructure Management Corporation (BCI)
11-Feb-25
$320 million (AUD value)
Target:
Pacific Smiles Group
Acquiror:
Genesis Capital
Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover
17-Dec-24
$962 million
Target:
Renewable assets in Chile involving hybrid solar power generation and storage
Acquiror:
Contour Global
Advised ContourGlobal (KKR) in the acquisition of 3 independent solar (Quillagua I & II, and Victor Jara) and BESS projects from Grenergy
04-Dec-24
$542 million (CAD value)
Target:
Heartland Generation
Acquiror:
TransAlta Corporation
Strategic advisor to Heartland Generation, one of Alberta's largest power generators and an Energy Capital Partners affiliate, on its sale to TransAlta Corporation
30-May-24
Pending
Undisclosed
Target:
Renewi plc’s UK Municipal Business
Acquiror:
Biffa Limited
Advising Renewi plc, a leading European waste-to-product company, on the divestiture of its UK Municipal operations to Biffa Limited, a leading UK-wide integrated waste management business
20-Feb-24
Pending
$185 million
Target:
myHomecare Group
Acquiror:
Australian Unity
Advising Australian Unity on its acquisition of myHomecare Group
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
29-Mar-23
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
11-Oct-22
$7.9 billion
Target:
Westinghouse Electric Company
Acquiror:
Brookfield Renewable Partners and Cameco
Advised the Independent Committee of Brookfield Renewable Partners, the flagship listed renewable power company of Brookfield Asset Management, in consortium with Cameco and other institutional partners, on the acquisition of Westinghouse Electric Company, one of the world’s largest nuclear services businesses, from Brookfield Business Partners
13-Sep-22
Undisclosed
Target:
InterGen N.V.’s UK business
Acquiror:
Bortela Capital s.r.o
Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
05-Oct-21
$175 million
Target:
Kao Data Ltd
Acquiror:
Infratil Ltd
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
08-Sep-21
Undisclosed
Target:
Hydrogen Technology & Energy Corporation (HTEC)
Acquiror:
I Squared Capital
Advising I Squared Capital, an independent global infrastructure investment manager, on its acquisition of a 35% equity interest in HTEC, a privately-held leader in the hydrogen energy transition
27-Jul-21
Undisclosed
Target:
Pulsant Limited
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services
17-May-21
Pending
$275 million
Target:
Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development
Acquiror:
Universities Superannuation Scheme (“USS”)
Advising Bruc OPT Energy Partners (“BROP”), a renewable energy JV owned by OPTrust and Mr. Juan Béjar, on the sale of a 50% stake in Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development, to funds managed by Universities Superannuation Scheme (“USS”), the largest pension scheme by assets in the UK
05-Apr-21
Undisclosed
Target:
Equity investment in NuScale Power LLC
Acquiror:
Various investors from Japan (led by JGC Holdings Corporation and IHI Corporation), South Korea (Doosan Heavy Industries) and the US (Sargent & Lundy)
Advised Fluor Corporation, a global engineering, procurement and construction company and the majority investor in NuScale, a leading developer of small modular reactor nuclear technology, on the equity capital raise for NuScale
29-Mar-21
Undisclosed
Target:
Worley’s Capital Projects Advisory business
Acquiror:
TSA Management
Advised ASX-listed Worley Limited on the sale of its Capital Projects Advisory business, a market leading provider of public infrastructure advisory services in Australia, New Zealand and Southeast Asia, to TSA Management (a portfolio company of Quadrant Private Equity)